Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1123-1133

  Tanaka, Tetsuji ^a   Utsunomiya, Tomoko ^a   Utsunomiya, Hirotoshi ^a   Umesaki, Naohiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

CPT 11; Irinotecan; Menopause; Ovarian failure; Topoisomerase I inhibitor

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRADIOL; ETOPOSIDE; FLUOROURACIL; FOLLITROPIN; IFOSFAMIDE; IRINOTECAN; LUTEINIZING HORMONE; MITOMYCIN; NEDAPLATIN; PACLITAXEL; PEPLEOMYCIN; PIRARUBICIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; ENZYME INHIBITOR;

ADULT; AMENORRHEA; ANAPHYLACTIC SHOCK; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLIMACTERIUM; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; FOLLITROPIN BLOOD LEVEL; GYNECOLOGIC CANCER; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL MALAISE LIKE SYMPTOM; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; UTERINE CERVIX CANCER; UTERUS CANCER; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MIDDLE AGED; OVARY; OVARY TUMOR; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN FAILURE, PREMATURE; OVARIAN NEOPLASMS; OVARY; PERIMENOPAUSE; PREMENOPAUSE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 47549107094     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1123     Document Type: Article

References (25)

1. Sutcliffe SB: Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease. Facts and thoughts. JAMA 242: 1898-1901, 1979.
2. Byrne J, Mulvihill JJ, Myers MH, Connelly RR, Naughton MD, Krauss MR, Steinhorn SC, Hassinger DD, Austin DF, Bragg K, et al: Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 317: 1315-1321, 1987.
3. Rivkees SA and Crawford JD: The regulationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259: 2123-2125, 1988.
4. Chapman RM, Sutcliffe SB and Malpas JS: Male gonadal dysfunction: a prospective study. JAMA 245: 1323-1328, 1981.
5. Koyama H, Wada T, Nishizawa Y, Iwanaga T and Aoki Y: Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39: 1403-1409, 1977.
6. Horning SJ, Hoppe RT, Kaplan HS and Rosenberg SA: Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 304: 1377-1382, 1981.
7. Bakchine H, Brauner R, Thibaud E, Rappaport R, Flamant F, Griscelli C, Lemerle J, Schaison G, Schweisguth O and Zucker JM: Chemotherapy and ovarian function. Retrospective analyses in 17 girls treated for malignant tumor of hematologic disease. Arch Fr Pediatr 43: 611-616, 1986.
8. Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C and De Placido S: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63: 799-803, 1991.
9. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, Robison LL and Sklar CA: Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 91: 1723-1728, 2006.
10. Sonmezer M and Oktay K: Fertility preservation in female patients. Hum Reprod Update 10: 251-266, 2004.
11. Wallace WH, Anderson RA and Irvine DS: Fertility preservation for young patients with cancer; who is at risk and what can be offered? Lancet Oncol 6: 209-218, 2005.
12. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4192, 1991.
13. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M and Ohashi Y: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31-37, 2000.
14. Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K and Izumi R: Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 95: 127-132, 2004.
15. Tanaka T, Kokawa K and Umesaki N: Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IlIb cervical squamous cell carcinoma: A pilot study. Eur J Gynaecol Oncol 26: 605-607, 2005.
16. Tanaka T, Umesaki N and Ogita S: Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases. Eur J Gynaecol Oncol 21: 377-379, 2000.
17. Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, Fujita K and Tanaka K: Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 97: 893-897, 2005.
18. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
19. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic cororectal cancer. N Engl J Med 343: 905-914, 2000.
20. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000.
21. Yamao T, Shirao K, Matsumura Y, Muro K, Yamada Y, Goto M, Chin K and Shimada Y: Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 12: 1729-1735, 2001.
22. Tobinai K and Hotta T: Clinical trials for malignant lymphoma in Japan. Jpn J Clin Oncol 34: 369-378, 2004.
23. Itabashi M, Inoue T, Amano Y and Sato K: Reproduction and developmental toxicity studies of CPT-11. Clin Res 24: 85-96, 1990.
24. Tanaka T, Umesaki N and Ogita S: Effects of shakuyaku-kanzoto on menopausal symptoms in an ovarian cancer patient treated with irinotecan HCI. J Trad Med 15: 456-457, 1998.
25. Utsunomiya T, Tanaka T, Utsunomiya H and Umesaki N: A novel molecular mechanism for anticancer drug-induced ovarian failure: irinotecan HCI, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. Int J Oncol 32: 991-1000, 2008.